← All Newamsterdam Pharma CO NV filings

Newamsterdam Pharma CO NV 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
NAMS
Newamsterdam Pharma CO NV
20-F/A: NewAmsterdam Pharma Restates 2022 Financials Due to Loss Per Share Calculation Errors
NewAmsterdam Pharma files an amended 20-F report to restate its 2022 and 2021 financial statements due to errors in calculating basic and diluted loss per share, identifying a material weakness in internal controls.